Author:
Van Cutsem E.,Hochster H.,Shitara K.,Mayer R.,Ohtsu A.,Falcone A.,Yoshino T.,Doi T.,Ilson D.H.,Arkenau H.-T.,George B.,Benhadji K.A.,Makris L.,Tabernero J.
Reference31 articles.
1. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA;Emura;Int J Oncol,2004
2. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2’-deoxyribonucleosides;Fukushima;Biochem Pharmacol,2000
3. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells;Emura;Int J Mol Med,2004
4. LONSURF® (trifluridine and tipiracil) tablets [prescribing information],2019
5. Randomized trial of TAS-102 for refractory metastatic colorectal cancer;Mayer;N Engl J Med,2015
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献